SEC Filings

10-Q
AVEXIS, INC. filed this Form 10-Q on 11/09/2017
Entire Document
 

AveXis, Inc.

 

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 

 

 

    

2017

    

2016

 

Cash flows from operating activities

 

 

 

 

 

 

 

Net loss

 

$

(136,386)

 

$

(57,637)

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

 

1,315

 

 

33

 

Stock-based compensation

 

 

23,595

 

 

22,713

 

Changes in operating assets and liabilities

 

 

 

 

 

 

 

Prepaid and other current assets

 

 

(4,355)

 

 

(2,908)

 

Other long-term assets

 

 

(1,228)

 

 

(848)

 

Accounts payable

 

 

6,624

 

 

1,051

 

Accrued expenses and other current liabilities

 

 

(1,461)

 

 

4,262

 

Accrued indemnification obligation

 

 

(1,669)

 

 

136

 

Net cash used in operating activities

 

 

(113,565)

 

 

(33,198)

 

Cash flows from investing activities

 

 

 

 

 

 

 

Capital expenditures

 

 

(23,364)

 

 

(11,702)

 

Net cash used in investing activities

 

 

(23,364)

 

 

(11,702)

 

Cash flows from financing activities

 

 

 

 

 

 

 

Proceeds from issuance of common stock, net of issuance costs

 

 

269,869

 

 

247,228

 

Payments of deferred offering costs

 

 

 —

 

 

(1,198)

 

Proceeds from exercise of stock options

 

 

1,258

 

 

218

 

Service-based restricted stock unit vesting

 

 

(417)

 

 

 —

 

Proceeds from exercise of stock warrants

 

 

 —

 

 

42

 

Net cash provided by financing activities

 

 

270,710

 

 

246,290

 

Net increase in cash and cash equivalents

 

 

133,781

 

 

201,390

 

Cash and cash equivalents, Beginning of Period

 

 

240,430

 

 

62,252

 

Cash and cash equivalents, End of Period

 

$

374,211

 

$

263,642

 

Supplemental Cash Flow Information

 

 

 

 

 

 

 

Capital expenditures in accounts payable and accrued liabilities

 

$

4,954

 

$

4,927

 

Deferred issuance costs for underwritten offering in accounts payable and accrued liabilities

 

$

 —

 

$

727

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

5


 


© AveXis, Inc. All Rights Reserved.